NASHVILLE, Tenn., April 11 /PRNewswire/ -- Cumberland Emerging
Technologies (CET) has announced the signing of a collaboration agreement with
the University of Mississippi School of Pharmacy (UM) to develop and
commercialize new pharmaceutical products.
With the shared goal of bringing early-stage research to the marketplace,
the parties have agreed to combine their strengths to take innovative new
products, based on research at UM, through the critical phases of development
and on to commercialization. The university and CET will work together to
pursue grant funding for these projects through programs like Small Business
Technology Transfer and Small Business Innovation Research, for which CET will
provide program management.
In addition to bringing new products to market, the parties will explore
opportunities for development of a Mississippi-based CET life sciences
incubator, similar to the facility CET developed in Nashville in 2002.
"We are excited to partner with CET to further the important work
initiated here," said Barbara Wells, dean of the UM School Of Pharmacy. "The
infrastructure support they provide will present our researchers with
increased opportunity to develop potentially life-saving medications and
technologies in our region."
"Aligning ourselves with outstanding academic research and training
programs like the University of Mississippi School of Pharmacy is a logical
progression in CET's development," said A.J. Kazimi, chief executive officer
of Cumberland Pharmaceuticals and CET. "By combining our expertise in drug
development and commercialization with the university's research initiatives,
we can facilitate the introduction of promising new products to the market."
Founded in 1908, the UM School of
Pharmacy ( http://www.pharmacy.olemiss.edu/ ) offers degree programs to
undergraduate and graduate students. Through the campus-based Research
Institute of Pharmaceutical Sciences and its two divisions, the National
Center for Natural Products Research and the Center for Pharmaceutical
Marketing and Management, the university conducts research to improve human
health and agricultural productivity. The university's Division of Technology
Management has successfully licensed 17 technologies over the past five years,
including three pharmaceutical candidates in clinical trials.
Cumberland Emerging Technologies, Inc. is a joint initiative between
Vanderbilt University, Cumberland Pharmaceuticals Inc. and the Tennessee
Technology Development Corporation. The mission of CET
( http://www.cet-fund.com ) is to bring biomedical technologies and products
conceived at Vanderbilt and other regional research centers to the commercial
marketplace. CET helps manage the development and commercialization process
for select projects and provides expertise on intellectual property,
regulatory, manufacturing and marketing issues that are critical to successful
new biomedical products.
SOURCE Cumberland Emerging Technologies, Inc.